Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBI: Biochemotherapy, Bevacizumab, and Ipilimumab in Metastatic Melanoma
NCT01743157Phase 2Completed
- Sponsor
- California Pacific Medical Center Research Institute
- Start
- Dec 2010
- Primary completion
- May 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and ipilimumab in melanoma, sponsored by California Pacific Medical Center Research Institute. Primary endpoint: Incidence of grade 4 bevacizumab-related toxicities and grade 3 proteinuria at 3 years. Started Dec 2010; status: completed.
02
Drugs
bevacizumabipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01743157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01743157.